Kevin M.Haigis, inTrends in Cancer, 2017 Trends KRASis the most commonly mutatedoncogenein human cancer, with particularly high frequency in cancers of the pancreas, colon, and lung. KRASmutation is associated with poor prognosis, yet there are no effective therapies to specifically treat cancers...
Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using amphiphile (Amph) modification of G12D and G12R mutant KRAS (mKRA...
Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, Pencreach E, Guenot D (2014) Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer 13: 58. Article Google Scholar Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N,...
colon, ovarian and uterus, myeloid leukemia, lymphomas, small-cell lung carcinomas (SCLC), and neuroblastoma, among others, most of which are aggressive and respond poorly to the current therapies.3,16However, unlike other common oncogenes,MYCis seldom mutated in cancer.3Nevertheless, it is ove...
G12R Figure 1 a), ranking among the top alterations, and commonly occurring in ovarian, esophagogastric, anduterine cancers[ 4 5 Download:Download high-res image (673KB) Download:Download full-size image Figure 1.Distribution of KRAS alleles/amplification and patient numbers in cancer. Mutation...
E. et al. Oncogenic KRAS and BRAF drive metabolic reprogramming in colorectal cancer. Mol. Cell Proteom. 15, 2924–2938 (2016). Article CAS Google Scholar Aguilera, O. et al. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. Oncotarget 7, 47954–47965 (2016)...
KRASG12Dmutation has an intrinsic wildtype and SOS1 guanine exchange activities while theKRASQ61mutation has deficiencies in GTP hydrolysis27,30. TheKRASG12Rmutation, which accounts for approximately 15% of theKRASmutations in pancreatic cancer but less than 1% of theKRASmutations in lung cancer,...
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C i
The Kirsten rat sarcoma virus gene (KRAS) is the most common tumor in human cancer, and KRAS plays an important role in the growth of tumor cells. Normal KRAS inhibits tumor cell growth. When mutated, it will continuously stimulate cell growth, resulting in tumor development. There are curren...